ES2384497T3 - Anticuerpos monoclonales neutralizantes contra el coronavirus asociado al síndrome respiratorio agudo severo - Google Patents

Anticuerpos monoclonales neutralizantes contra el coronavirus asociado al síndrome respiratorio agudo severo Download PDF

Info

Publication number
ES2384497T3
ES2384497T3 ES10151641T ES10151641T ES2384497T3 ES 2384497 T3 ES2384497 T3 ES 2384497T3 ES 10151641 T ES10151641 T ES 10151641T ES 10151641 T ES10151641 T ES 10151641T ES 2384497 T3 ES2384497 T3 ES 2384497T3
Authority
ES
Spain
Prior art keywords
sars
cov
antibody
mabs
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10151641T
Other languages
English (en)
Spanish (es)
Inventor
Shibo Jiang
Yuxian He
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York Blood Center Inc
Original Assignee
New York Blood Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Blood Center Inc filed Critical New York Blood Center Inc
Application granted granted Critical
Publication of ES2384497T3 publication Critical patent/ES2384497T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES10151641T 2005-02-08 2006-02-08 Anticuerpos monoclonales neutralizantes contra el coronavirus asociado al síndrome respiratorio agudo severo Expired - Lifetime ES2384497T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65104605P 2005-02-08 2005-02-08
US651046 2005-02-08
US14192505A 2005-05-31 2005-05-31
US141925 2005-05-31

Publications (1)

Publication Number Publication Date
ES2384497T3 true ES2384497T3 (es) 2012-07-05

Family

ID=36793717

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10151641T Expired - Lifetime ES2384497T3 (es) 2005-02-08 2006-02-08 Anticuerpos monoclonales neutralizantes contra el coronavirus asociado al síndrome respiratorio agudo severo

Country Status (10)

Country Link
EP (1) EP1855719A4 (de)
JP (1) JP2008529504A (de)
AT (1) ATE556717T1 (de)
AU (1) AU2006213775C1 (de)
BR (1) BRPI0606148A2 (de)
CA (1) CA2595780A1 (de)
ES (1) ES2384497T3 (de)
MX (1) MX2007009512A (de)
NZ (1) NZ560328A (de)
WO (1) WO2006086561A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20210458T1 (hr) 2014-06-12 2021-05-14 Universidade Do Porto - Reitoria Cjepivo za imunološki kompromitirane domaćine
CA3166967A1 (en) * 2020-02-06 2021-08-12 Bert Schepens Corona virus binders
EP4107180A4 (de) * 2020-02-19 2024-05-08 United Biomedical Inc. Designer-peptide und -proteine zur detektion, prävention und behandlung von coronavirus-krankheit 2019 (covid-19)
CN113292649B (zh) * 2020-02-24 2022-08-12 中国科学院微生物研究所 新型冠状病毒的人源单克隆抗体及其应用
CN113292650B (zh) * 2020-02-24 2022-08-12 中国科学院微生物研究所 新型冠状病毒的人源单克隆抗体及其应用
WO2021183195A1 (en) * 2020-03-09 2021-09-16 1.Abcellera Biologics Inc. Anti-coronavirus antibodies and methods of use
CN113391064B (zh) * 2020-03-13 2024-11-22 科美诊断技术股份有限公司 用于检测新型冠状病毒中和抗体的受体试剂及其应用
CN111560074B (zh) * 2020-03-20 2021-07-09 中山大学 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白单区域亚单位纳米疫苗
CN111983226A (zh) * 2020-03-25 2020-11-24 新加坡国立大学 SARSr-CoV抗体的检测
WO2021202893A1 (en) * 2020-04-03 2021-10-07 Nonigenex, Inc. Detecting adaptive immunity to coronavirus
WO2021221137A1 (ja) * 2020-05-01 2021-11-04 花王株式会社 抗ＳＡＲＳ－ＣｏＶ－２抗体を用いた医薬品及び検査キット
CN112010966B (zh) * 2020-05-15 2021-03-19 潍坊医学院 一种针对新冠病毒棘突蛋白非rbd区的单克隆抗体及其应用
WO2021238910A1 (en) * 2020-05-25 2021-12-02 Guo Bingshi Anti-coronavirus spike protein antibodies and uses thereof
CN112017782A (zh) * 2020-06-01 2020-12-01 北京松果天目健康管理有限公司 SARS-CoV-2易感性的检测方法及新冠病毒重症风险预测方法
AU2021297998A1 (en) * 2020-06-25 2022-12-15 Gliknik Inc. ACE2-Fc fusion proteins and methods of use
MX2023000267A (es) * 2020-07-16 2023-02-13 Caregen Co Ltd Peptido con actividad neutralizante contra el coronavirus 2 del sindrome respiratorio agudo grave.
CN113945714B (zh) * 2020-07-16 2023-01-31 南京蓬勃生物科技有限公司 新型冠状病毒中和抗体类药物中和能力的检测方法
CN112010984B (zh) * 2020-08-04 2021-10-12 广州千扬生物医药技术有限公司 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白多聚体纳米疫苗
WO2022044573A1 (ja) 2020-08-26 2022-03-03 国立大学法人熊本大学 コロナウイルススパイク蛋白に対するヒト抗体またはその抗原結合断片
CN114181301B (zh) * 2020-09-14 2023-04-28 复旦大学 针对SARS-CoV-2的无ADE效应的中和抗体
CN113156129B (zh) * 2021-01-13 2022-04-05 广东菲鹏生物有限公司 中和抗体高敏检测方法及产品
US20240158477A1 (en) * 2021-01-27 2024-05-16 Bioduro (Jiangsu) Co., Ltd. Antibody against sars-cov-2
CN115141272B (zh) * 2021-01-31 2024-06-25 中南大学湘雅医院 新型冠状病毒单克隆抗体xy1及其应用
CN116973566A (zh) * 2021-02-03 2023-10-31 广东菲鹏生物有限公司 一种鉴别结合突变型抗原的抗体的方法及试剂
EP4089112A1 (de) * 2021-05-14 2022-11-16 Ustav organicke chemie a biochemie AV CR, v.v.i. Antikörper mit bindung an rbd des spike-proteins von sars-cov-2 und verfahren zur quantifizierung von schützenden antikörpern gegen sars-cov-2
WO2023148641A1 (en) * 2022-02-02 2023-08-10 Translational Health Science And Technology Institute Monoclonal antibodies specific to receptor binding domain of sars-cov2 and uses thereof

Also Published As

Publication number Publication date
EP1855719A2 (de) 2007-11-21
AU2006213775C1 (en) 2011-11-03
BRPI0606148A2 (pt) 2009-06-02
AU2006213775B2 (en) 2010-11-11
EP1855719A4 (de) 2009-11-04
CA2595780A1 (en) 2006-08-17
NZ560328A (en) 2010-05-28
ATE556717T1 (de) 2012-05-15
JP2008529504A (ja) 2008-08-07
WO2006086561A3 (en) 2009-04-23
WO2006086561A2 (en) 2006-08-17
AU2006213775A1 (en) 2006-08-17
MX2007009512A (es) 2008-02-21

Similar Documents

Publication Publication Date Title
ES2384497T3 (es) Anticuerpos monoclonales neutralizantes contra el coronavirus asociado al síndrome respiratorio agudo severo
US7629443B2 (en) Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
He et al. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies
US11505597B2 (en) Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
He et al. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines
CN1914226B (zh) SARS-CoV抗体及其使用方法
He et al. Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine
CN104245731B (zh) 抗乙型流感病毒的广泛保护性人单克隆抗体及其使用方法
TW202200612A (zh) SARS-Cov-2 (SARS2, COVID-19)抗體
US20060240515A1 (en) Soluble fragments of the SARS-CoV spike glycoprotein
CN107708726B (zh) 抗体介导的切昆贡亚热病毒的中和
Tripp et al. Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins
WO2007044695A2 (en) ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
CN101522208A (zh) 抗严重急性呼吸综合征相关冠状病毒的中和单克隆抗体
EP2193802B1 (de) Neutralisierung monoklonaler Antikörper gegen mit schwerem akutem Respirationssyndrom assoziiertem Coronavirus
He et al. A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity
Bian et al. Conserved amino acids W423 and N424 in receptor-binding domain of SARS-CoV are potential targets for therapeutic monoclonal antibody
Fouladirad et al. Development of coronavirus treatments using neutralizing antibodies. Microorganisms. 2021; 9: 165
Spike Receptor-Binding Domain of Severe Acute
Mnyamana Antibody production with synthetic peptides against human Coronavirus-NL63 ORF3 protein
HK40072444A (en) Antibody-mediated neutralization of chikungunya virus
Spike Antigenic and Immunogenic
Spike Identification of an Antigenic Determinant